Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN2477783 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-C1q antibody
- Antibody type
- Polyclonal
- Description
- Purified
- Reactivity
- Human
- Host
- Sheep
- Isotype
- IgG
- Vial size
- 1 mL
Submitted references Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment.
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.
Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity.
Influence of thyroid state on the specific binding of noradrenaline to a cardiac particulate fraction and on catecholamine-sensitive cardiac adenylate cyclase activity.
Hwang HY, Duvall MR, Tomlinson S, Boackle RJ
Molecular immunology 2008 May;45(9):2570-80
Molecular immunology 2008 May;45(9):2570-80
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.
Cragg MS, Glennie MJ
Blood 2004 Apr 1;103(7):2738-43
Blood 2004 Apr 1;103(7):2738-43
Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity.
Sárvári M, Vágó I, Wéber CS, Nagy J, Gál P, Mák M, Kósa JP, Závodszky P, Pázmány T
Journal of neuroimmunology 2003 Apr;137(1-2):12-8
Journal of neuroimmunology 2003 Apr;137(1-2):12-8
Influence of thyroid state on the specific binding of noradrenaline to a cardiac particulate fraction and on catecholamine-sensitive cardiac adenylate cyclase activity.
Wollenberger A, Will-Shahab L
Recent advances in studies on cardiac structure and metabolism 1976;9:193-203
Recent advances in studies on cardiac structure and metabolism 1976;9:193-203
No comments: Submit comment
No validations: Submit validation data